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Abstract: Hypoglycemia is the rate-limiting factor that often prevents patients with diabetes 
from safely and effectively achieving their glycemic goals. Recent studies have reported that 
severe hypoglycemia is associated with a significant increase in the adjusted risks of major 
macrovascular events, major microvascular events, and mortality. Minor hypoglycemic episodes 
can also have serious implications for patient health, psychological well being, and adherence to 
treatment regimens. Hypoglycemic events can impact the health economics of the patient, their 
employer, and third-party payers. Insulin treatment is a key predictor of hypoglycemia, with one 
large population-based study reporting an overall prevalence of 7.1% (type 1 diabetes mellitus) 
and 7.3% (type 2 diabetes mellitus) in insulin-treated patients, compared with 0.8% in patients 
with type 2 diabetes treated with an oral sulfonylurea. Patients with type 1 diabetes typically 
experience symptomatic hypoglycemia on average twice weekly and severe hypoglycemia once 
annually. The progressive loss of islet cell function in patients with type 2 diabetes results in a 
higher risk of both symptomatic and unrecognized hypoglycemia over time. Patients with diabetes 
who become hypoglycemic are also more susceptible to developing defective counter-regulation, 
also known as hypoglycemia awareness autonomic failure, which is life-threatening and must be 
aggressively addressed. In patients unable to recognize hypoglycemia symptoms, frequent home 
monitoring or use of continuous glucose sensors are critical. Primary care physicians play a key 
role in the prevention and management of hypoglycemia in patients with diabetes, particularly 
in those requiring intensive insulin therapy, yet physicians are often unaware of the multitude 
of consequences of hypoglycemia or how to deal with them. Careful monitoring, adherence to 
guidelines, and use of optimal treatment combinations are all important steps toward improv-
ing care in patients with diabetes. The most important goals are for primary care physicians to 
recognize that every patient treated with antihyperglycemic medications is at risk of iatrogenic 
hypoglycemia and to ask patients about hypoglycemia at every visit.
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Increasing awareness of hypoglycemia
Achieving optimal glycemic control is a priority for the management of diabetes in 
order to minimize the risk of long-term complications. However, iatrogenic (therapy-
induced) hypoglycemia is a common side effect of antihyperglycemic therapies. 
In fact, hypoglycemia is a key limiting factor in the successful glycemic management 
of many diabetes patients, with recent studies indicating a substantial prevalence of 
hypoglycemic events, not only in patients with type 1 diabetes mellitus, but also in 
patients with type 2 diabetes mellitus, particularly in those who require intensive 
insulin therapy and frequent blood glucose monitoring to achieve optimal glycemic 
control.1,2
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The detrimental impact of hypoglycemia is highlighted in 
a number of recently published studies, which have mainly 
focused on the effects of severe hypoglycemic events. In the 
past, the demonstration of a direct relationship between hypo-
glycemia and mortality has been controversial.   However, 
new studies have reported that severe hypoglycemia is 
associated with a significant increase in the adjusted risks of 
major macrovascular events (hazards ratio [HR] 2.88), major 
microvascular events (HR 1.81), and mortality (HR 2.69), as 
shown in Figure 1.3 The mortality rate among patients with 
severe hypoglycemia was 19.5%, compared with 9% among 
those who did not report severe hypoglycemia.3 Recent and 
ongoing studies in both the US and Europe also point to the 
substantial economic costs associated with hypoglycemia, 
which suggest that hypoglycemic events have a wide-ranging 
economic impact on the health care system, the patient, and 
the patient’s family, friends, and caregivers, as well as an 
  estimated total annual cost per episode of up to $1500. Finally, 
failure to recognize and treat severe hypoglycemia can result 
in devastating immediate neurological consequences, such 
as altered consciousness, seizures, and coma.
While severe hypoglycemic events are undoubtedly 
dangerous to patients, equally important are nonsevere 
hypoglycemic events, which are frequently and incorrectly 
dismissed as unimportant because they can be   asymptomatic. 
In fact, nonsevere hypoglycemic events are actually much 
more common than severe hypoglycemic events, yet, 
because symptoms of hypoglycemia are nonspecific, even 
symptomatic, nonsevere hypoglycemic episodes may go 
unrecognized. Even if they are recognized, they may not be 
significant enough to be remembered by the patient and to 
be mentioned to the primary care physician and are therefore 
also significantly under-reported.4 Recurrent episodes of 
untreated hypoglycemia can lead to hypoglycemia-associated 
autonomic failure5–7 (Figure 2), an impaired ability of the 
body to counter-regulate subsequent and more serious events, 
which leads to unawareness of hypoglycemia. The blood 
glucose level at which the body normally initiates a response 
is lowered, and serious clinical effects may occur before 
symptomatic awareness of hypoglycemia. Hypoglycemia 
also commonly goes undetected when it occurs during the 
night. Nocturnal hypoglycemia can lead to serious clinical 
consequences, including sudden death during sleep, thought 
to be a result of cardiac rate and rhythm disturbances in 
response to prolonged nocturnal hypoglycemia.4–7
There are multiple definitions of hypoglycemia and con-
flicting data on the incidence of hypoglycemia available in the 
scientific literature. Combined with the fact that hypoglycemic 
events often go undetected for a number of different reasons, 
this ultimately means that primary care physicians on the front 
line of diabetes care, who are responsible for guiding therapy 
to achieve euglycemic control in patients with diabetes, may 
not be aware of the significant impact of hypoglycemia.
The purpose of this review is to discuss the importance of all 
hypoglycemic events in the successful management of patients 
with diabetes, with the aim of improving understanding of the 
impact and consequences of hypoglycemia,   emphasizing new 
data regarding the incidence of hypoglycemia in type 1 and 
type 2 diabetes patients taking insulin, exploring new meth-
ods to aid the diagnosis and treatment of hypoglycemia, and 
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Figure 1 Frequency of adverse clinical outcomes after the occurrence of severe hypoglycemia event.
Copyright © 2010, Massachusetts Medical Society. Reprinted with permission from Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events 
and death. N Engl J Med. 2010;363(15):1410–1418.
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highlighting the need for newer therapeutic agents with a lower 
risk of causing hypoglycemia.
Epidemiology of hypoglycemia
Definitions
Hypoglycemia occurs when blood glucose concentrations fall 
below the level necessary to maintain the body’s requirement 
for energy and stability in a proper manner.6 Currently, there 
is no consensus or standardized definition of hypoglycemia. 
A number of different scientific organizations offer   different 
definitions and often there are substantial differences in 
  interpreting and reporting hypoglycemic events among 
  investigators participating in clinical trials with different 
pharmaceutical companies, and this can lead to a great deal of 
confusion as to what constitutes a hypoglycemic event.
Among the earliest clinical definitions of hypoglycemia 
was the presence of Whipple’s triad, incorporating observa-
tions of decreased blood glucose concentrations, symptoms 
compatible with hypoglycemia, and rapid attenuation of those 
symptoms upon correction of blood glucose, a definition that 
remains clinically relevant today. Other definitions have 
been provided by professional medical organizations that 
include the American Diabetes Association (ADA) and the 
American Association of Clinical Endocrinologists (AACE) 
in an attempt to define the clinical severity of hypoglycemia, 
classify events according to the presence or absence of a 
blood glucose test, and identify a universal threshold level 
for blood glucose at which hypoglycemia is diagnosed. Each 
organization differs in their set thresholds, which range 
from ,3.9 mmol/L (,70 mg/dL) down to ,3 mmol/L 
(,54 mg/dL).4,8–10 The US Food and Drug Administration 
(FDA)   recommends following the guidelines set by the ADA 
in order to achieve some level of consistency.11
The ADA Workgroup on Hypoglycemia has defined 
  hypoglycemia as “all episodes of abnormally low blood 
glucose concentration that expose the individual to potential 
harm”,9 and both this workgroup and the current ADA guide-
lines (2012) define hypoglycemia as a fasting blood glucose 
of ,3.9 mmol/L (,70 mg/dL).9,10 This threshold is higher 
than most values commonly used in clinical trials, because 
the aim of these guidelines is not to estimate the prevalence 
of hypoglycemia, but to try to prevent it from happening. The 
ADA suggests that this threshold level will allow the patient 
time to take action to prevent hypoglycemia and allows for a 
margin of error with blood glucose self-monitoring devices. 
The guidelines also divide the definitions of hypoglycemia 
into asymptomatic (hypoglycemia not accompanied by typical 
symptoms) and symptomatic (hypoglycemia accompanied by 
typical symptoms), and provide a detailed definition of severe 
hypoglycemia as an episode in which the patient is unable 
to self-treat and requires external intervention and assistance 
and as an episode which may be accompanied by neurological 
effects sufficient to induce seizure or coma.
Patient perceptions of hypoglycemia can differ substantially 
from clinical definitions, affecting the true number of events 
that are reported to primary care physicians. A patient who 
experiences hypoglycemia for the first time will often refer 
to that event as being “severe” because of fears that they have 
become powerless to prevent their own morbidity without out-
side assistance.8 Primary care physicians must understand that 
hypoglycemic events are potentially life-altering.   Therefore, 
patients and their families must be educated to minimize the 
frequency of the events as well as recognize, predict, and 
appropriately manage acute hypoglycemia.
Prevalence
Many clinical reviews have attempted to determine the exact 
prevalence of hypoglycemia among patients with diabetes. 
Clinicians may underestimate the frequency of hypoglycemia 
in their patient population with type 2 diabetes.12 In advanced 
type 2 diabetes, disease progression and loss of β-cell   function 
parallel a loss in hormonal counter-regulation leading to 
  hypoglycemia.5 Thus, patients with advanced type 2 diabetes 
who are candidates for therapeutic intensification with insulin 
therapy will have a higher risk of developing hypoglycemia 
than those who are at an earlier stage of the disease.5,12
Studies have shown that the prevalence of   hypoglycemia 
in patients with advanced type 2 diabetes who require   insulin 
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Figure 2 Diagrammatic representation of the concept of hypoglycemia-associated 
autonomic failure.
Copyright  ©  2011,  vendome  Group.  Reprinted  with  permission  from  Unger  J, 
Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. 
Postgrad Med. 2011;123(4):81–91.
Abbreviation: BG, blood glucose.
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treatment may be the same as that in patients with type 1 
diabetes. The Diabetes Audit and Research in Tayside, Scotland 
(DARTS) study of 367,501 people, 8655 of whom had diabe-
tes, identified a total of 244 episodes of severe hypoglycemia 
in 160 patients. The overall prevalence was 7.1% in patients 
with type 1 diabetes and 7.3% in patients with type 2 diabetes 
treated with insulin, compared with 0.8% in patients with 
type 2 diabetes treated with an oral sulfonylurea (Table 1).12 
A subsequent DARTS study compared a selected cohort of 
type 1 diabetes and insulin-treated type 2 diabetes patients 
and confirmed that the incidence of severe hypoglycemia in 
patients was higher than previously reported, and that insulin 
treatment was a key predictor of hypoglycemia in this popu-
lation.13 A multicenter study of 11,140 patients with type 2 
diabetes from across 20   different countries found that during 
a median follow-up period of 5 years, 2.1% of patients experi-
enced a severe   hypoglycemic event. When assessed according 
to treatment group, 2.7% of those who received intensive 
blood glucose control experienced a severe hypoglycemic 
event, compared with only 1.5% of the standard blood glucose 
control group.3 The annual hypoglycemic rates according to 
treatment can be seen in Table 2.3
Research also suggests that the incidence of   hypoglycemia 
is particularly high among patients treated with insulin over 
extended periods of time, again reinforcing the idea that 
advanced disease progression and increased insulin use sub-
sequently increases the risk of hypoglycemia. The UK Study 
Group found that the incidence of severe   hypoglycemia in 
patients with type 1 diabetes treated with insulin for .15 years 
was three times higher than in those treated for ,5 years. 
In patients with type 2 diabetes, the prevalence of severe 
hypoglycemia increased from 7% to 25% when comparing 
patients treated with insulin for ,2 years with those treated 
for .5 years, respectively.14
Mild symptomatic and asymptomatic hypoglycemia are 
even more common than severe hypoglycemia,   accounting for 
up to 88% of all hypoglycemic events.15 Indeed, it has been 
estimated that blood glucose levels may be ,2.7–3.3 mmol/L 
(,50–60 mg/dL) up to 10% of the time.5 Retrospective esti-
mates of the incidence of mild, symptomatic hypoglycemia 
have varied from 29 to 162 episodes per patient per year.13,14,16 
Data from a number of other   studies suggest that nonsevere 
hypoglycemic events occur in 24%–60% of patients with dia-
betes.15 This variability likely reflects the difficulty in recall-
ing events with any accuracy beyond one week.   Prospective 
studies have indicated that the majority of insulin-treated 
patients experience an average of two symptomatic epi-
sodes per week.5 The UK Hypoglycaemia Study Group also 
reported a concurrent increase in mild hypoglycemic events, 
from 0.1 events/patient per year to 0.7 events/patient per year, 
in patients treated with insulin for .5 years compared with 
those treated for ,2 years.14
Though the risk of iatrogenic hypoglycemia is highest 
among patients treated with insulin, there are risks associated 
with other treatments. Early in the course of progression of 
type 2 diabetes, patients may respond to oral antidiabetic 
drugs, such as metformin or thiazolidinediones, and to 
  sulfonylureas. Sulfonylurea therapy, which increases insulin 
output from the pancreas, is one of the key contributors to 
hypoglycemia in patients with type 2 diabetes who are early 
in the progression of the disease. Hypoglycemic risk is high-
est with long-acting sulfonylureas, such as chlorpropamide 
and glibenclamide, while shorter-acting sulfonylureas, 
such as glipizide, are associated with a much lower risk. 
Prandial blood glucose regulators, such as repaglinide and 
nateglinide, also have a low hypoglycemic potential. The 
risk of hypoglycemia with oral antidiabetes drugs is variable 
and, as with sulfonylureas, depends upon their respective 
pharmacokinetic and pharmacodynamic profiles. Though 
the majority of these drugs are associated with a lower risk 
of hypoglycemia, it is important to remember that if insulin 
or insulin secretagogues, such as a sulfonylurea, are added 
into the treatment regimen as the disease progresses, the risk 
of hypoglycemia will increase.17
The incidence of type 2 diabetes is projected to increase 
in coming years, while the average age of patients with type 2 
diabetes is decreasing; therefore, the number of patients 
with advanced type 2 diabetes, for whom sulfonylureas and 
oral antidiabetes drugs will not provide sufficient glycemic 
control, and who will require the addition of insulin to their 
treatment regimen, is also likely to increase dramatically. 
Combined with increasingly tighter glycemic targets, this 
may contribute to an increasing prevalence of hypoglycemia 
in the future.
Table  1  Incidence  of  severe  hypoglycemia  requiring  NHS 
resources
Type of diabetes Treatment modality Incidence
Type 1 Insulin 11.5 (9.4–13.6)
Type 2 Insulin 11.8 (9.5–14.1)
Type 2 SU tablets 0.9 (0.6–1.3)
Type 2 Metformin or diet 0.05 (0.01–0.2)
Note: Data are events expressed per 100 patient-years (95% CI).
Copyright © 2003, American Diabetes Association. Reprinted with permission from 
Leese GP, wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring 
emergency treatment in type 1 and type 2 diabetes: a population-based study of 
health service resource use. Diabetes Care. 2003;26(4):1176–1180.
Abbreviations:  CI,  confidence  interval;  NHS,  Ninewells  Hospital  and  Medical 
School (United Kingdom); SU, sulfonylurea. 
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Consequences of hypoglycemia
Hypoglycemia is both a psychological and pathophysi-
ological barrier to optimal glycemic control in patients with 
diabetes. The associated physical morbidity ranges from 
unpleasant symptoms, such as anxiety, palpitations, tremors, 
sweating, hunger, and paresthesia, to more serious neuro-
logical sequelae, including behavioral changes, cognitive 
dysfunction, seizures, coma, and death.5
Neurological impairment
The brain relies on blood glucose for fuel, so hypoglycemia 
is, not surprisingly, linked to neurological defects. Two main 
areas of brain function are reported to be affected, ie, cogni-
tive ability, most typically the hippocampal function such 
as memory, and affective ability, affecting mood and levels 
of anxiety.5,18 Typically, blood glucose levels of ,1 mmol/L 
(18 mg/dL), termed neuroglycopenia, result in coma, loss 
of consciousness, and death. Even in cases where neuro-
glycopenia is not fatal, severe neurological impairments 
can lead to permanent brain damage. Fortunately, severe 
neurological defects are relatively rare, even in patients 
who experience recurrent hypoglycemia. However, less 
profound hypoglycemia, for example, where blood glucose 
levels are ,2 mmol/L (36 mg/dL), can still interfere with 
the patient’s ability to perform everyday tasks, leading to 
cognitive deterioration, irritability, belligerent behaviors, 
drowsiness, blurred vision, difficulties in speaking and 
communicating, confusion, and faintness.6 These effects 
can make performance of certain tasks, such as driving, 
much more dangerous.19   Hypoglycemia-induced neuro-
logical impairment can be particularly dangerous in the 
elderly and can lead to accelerated onset of dementia. One 
study quantified the risk of dementia attributable to hypo-
glycemia as 2.39% per year.20 However, the precise effects 
of hypoglycemia on cognitive abilities remain somewhat 
controversial. A range of studies show different outcomes 
from impairment to enhancement to no change. It has 
been suggested that recurrent hypoglycemia may not affect 
cognitive function during periods of euglycemia, but could 
significantly impact future performance at times of hypo-
glycemia instead.18 Because recurrent hypoglycemia lowers 
the blood glucose concentration at which symptomatic and 
hormonal responses are initiated, cognitive impairment and 
subclinical brain damage may occur prior to the onset of 
visible symptoms of hypoglycemia.
Cardiovascular outcomes
As with neurological consequences, there is controversy over 
the effects of hypoglycemia on cardiovascular outcomes. 
There have been multiple anecdotal reports and observational 
studies suggesting that hypoglycemia may increase the risk 
of acute coronary syndromes and increase the risk of death 
in patients hospitalized for myocardial infarction. A number 
of trials, in particular the Action to Control Cardiovascular 
Risk in   Diabetes (ACCORD) trials, investigating the effects 
of intensive blood glucose control on macrovascular outcomes 
in patients with type 2 diabetes, have demonstrated increased 
mortality rates in patients who experienced hypoglycemia.21,22 
Table 2 Episodes of severe and minor hypoglycemia in all study participants and according to treatment group
Variable All participants 
(n = 11,140)
Intensive 
blood glucose 
control 
(n = 5571)
Standard 
blood glucose 
control 
(n = 5569)
Hazards ratio 
(95% CI)
Severe hypoglycemia 
  Patients (n, %) 
  Episodes (n) 
 1  
 2  
  $3 
  Rate (person/year)
 
 
231 (2.1) 
184 
35 
12 
0.006
 
 
150 (2.7) 
120 
22 
8 
0.007
 
 
81 (1.5) 
64 
13 
4 
0.004
1.86 (1.40–2.40)
Minor hypoglycemia 
  Patients (n, %) 
  Episodes (n) 
 1  
 2  
  $3 
  Rate (person/year)
 
 
4975 (44.7) 
2610 
671 
1694 
1.1
 
 
2898 (52.0) 
1529 
397 
972 
1.2
 
 
2077 (37.3) 
1081 
274 
722 
0.9
1.58 (1.49–1.68)
Copyright © 2010, Massachusetts Medical Society. Reprinted with permission from Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events 
and death. N Engl J Med. 2010;363(15):1410–1418.
Abbreviations: BG, blood glucose; CI, confidence interval.
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However, a meta-analysis of various trials showed that intensive 
blood glucose control reduced the risk of myocardial infarction 
by 15%, with no adverse effect on the risk of death, although the 
risk of severe hypoglycemia was increased.23 Furthermore, post 
hoc analyses suggest the increased mortality rates observed in 
the ACCORD study may not be directly explained by high rates 
of hypoglycemia.24 The exact reason for the observed increase 
in mortality rates remains unclear. It was not attributed to any 
particular drug used in the study, although many different drug 
regimens and combinations were used in ACCORD to achieve 
tight glycemic control. Thus, attributing the increased risk to 
any one drug is extremely difficult.
Hypoglycemia unawareness
Repeated hypoglycemic events can lead to hypoglycemia 
unawareness, whereby hormonal, autonomic, sympathetic 
neural, and adrenomedullary responses are attenuated, 
such that the warning symptoms of developing hypogly-
cemia are essentially lost. This subsequently compromises 
natural behavioral defenses against hypoglycemia, such as 
the ingestion of food, so that instead of an episode of mild 
hypoglycemia developing that can be easily self-managed 
by the patient, more serious episodes of hypoglycemia may 
occur that require external intervention. Indeed, studies have 
shown that adults with type 1 diabetes who have impaired 
awareness of hypoglycemia are much more likely to be 
exposed to asymptomatic hypoglycemia and are at higher 
risk of developing severe hypoglycemia than those with 
normal awareness. A 4-week study that measured capillary 
blood glucose four times daily demonstrated that patients 
with hypoglycemia unawareness exhibit twice the frequency 
of all types of hypoglycemia (7.9 versus 3.7 in those with 
normal awareness), with seven times the incidence of asymp-
tomatic hypoglycemic events (3.7 versus 0.5) and an annual 
prevalence of severe hypoglycemia of 53% versus just 5% 
in those with normal awareness.25
Hypoglycemia unawareness occurs as a result of a physi-
ological response to recurrent hypoglycemic events known as 
hypoglycemia-associated autonomic failure,5–7 as described 
earlier (see Figure 2).7 It is proposed that, over time, repeated 
episodes of mild hypoglycemia cause the normal glycemic 
thresholds for initiating sympathoadrenal, symptomatic, and 
cognitive responses to subsequent hypoglycemia to shift 
towards lower blood glucose concentrations. This impairs 
the natural defense mechanisms required for prevention 
and reversal of hypoglycemia. Hypoglycemia-associated 
autonomic failure creates a vicious circle, because patients 
with type 1 diabetes already have a defective blood glucose 
counter-regulatory response. Hypoglycemia unawareness 
ultimately leads to a significantly reduced detection of hypo-
glycemia in the clinical setting and to further and more severe 
episodes of hypoglycemia.5 Three independent studies have 
shown that as little as 2–3 weeks of scrupulous avoidance of 
hypoglycemia can reverse hypoglycemia unawareness.5
Psychological consequences
The psychological consequences of hypoglycemia include 
subsequent fear of hypoglycemia, guilt relating to fear of 
  hypoglycemia, failure to comply with therapeutic regimens, 
high levels of anxiety, and low levels of satisfaction and 
  happiness. Fear of hypoglycemia is a particularly important 
  problem and is becoming almost as much of a barrier to 
  glycemic control as hypoglycemia itself.26 The Hypoglycemia 
Fear Survey (HFS), first published in 1987, and its updated 
counterpart HFS-II, are used to measure behaviors (HFS-B) 
and worries (HFS-W) related to hypoglycemia in adults with 
type 1 diabetes. They describe behaviors that patients may 
engage in to avoid hypoglycemia, such as maintaining higher 
blood glucose levels than recommended, avoiding being alone, 
and limiting exercise or physical activity, or concerns they may 
have about hypoglycemic episodes, such as nocturnal episodes. 
HFS-B and HFS-W scores have been shown to be significantly 
higher in women than in men and among patients who have 
experienced severe hypoglycemia in the past compared with 
those that have not.27
Fear of hypoglycemia is not just a problem for patients 
with diabetes, but also for the primary care physicians who 
treat them. The evidence suggests that if patients experience 
repeated severe hypoglycemic events, both the patient’s and 
the physician’s subsequent treatment policy are affected. One 
study reviewed hospital records and examined daily insulin 
doses and glycated hemoglobin (HbA1c) levels 0–3 months 
before and 2–6, 7–11, and 12–16 months after an episode of 
severe hypoglycemia (coma and/or convulsion) in patients 
with insulin-dependent diabetes. Forty-three patients expe-
rienced a total of 48 episodes of severe hypoglycemia, with 
five patients experiencing two events. It was found that, in 
69% of these cases, either the physician or patient or both 
decreased the daily insulin dose. Furthermore, physicians 
decreased the insulin dose in 14 of 33 patients in whom the 
cause of hypoglycemia was preventable and due to a cause 
other than erroneous administration of excess insulin.28
Economic costs
The economic impact of hypoglycemia has been examined 
in a number of studies in the US and Europe. The economic 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
62
UngerDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
costs range in their impact across the health care system, the 
patient and family, friends, and unpaid caregivers. Costs to 
the patient can include loss of work productivity, direct and 
indirect medical costs, and loss of earnings through extended 
periods of unemployment. Episodes requiring hospitaliza-
tion are particularly costly.29,30 One study conducted in 
the UK examined 244 episodes of severe hypoglycemia in 
160 patients with type 1 or type 2 diabetes over the course 
of one year and estimated the total cost of emergency treat-
ment for these events to be approximately £92,078,12 which 
equates to an average cost of almost £400 per episode. 
Several US studies have estimated the annual total costs per 
patient attributable to hypoglycemia to be between $1400 
and $1500, and have also estimated medical and indirect 
costs and estimated work days lost per hypoglycemic event 
(Tables 3 and 4).29 However, nonsevere hypoglycemic events 
also have a substantial economic impact. A retrospective 
review performed in Canada demonstrated that nonsevere 
hypoglycemic events accounted for 13% of all out-of-pocket 
costs related to diabetes.31 Nonsevere hypoglycemic events 
reportedly occur more frequently on work days, significantly 
impacting work productivity and generating substantial costs 
for the employer and the employee. A recent multicountry 
study assessing the impact of nonsevere hypoglycemic events 
in a working population determined that lost productivity 
costs range from $15.26 to $93.47 per event and account 
for 8.3–15.9 hours of lost work time. When events occurred 
during the workday, 18.3% of respondents missed an average 
of 9.9 hours of work. When they occurred outside of work, 
hypoglycemic events led to 23.7% of respondents arriv-
ing late to work or missing a full day. The impact on work 
productivity was most substantial for episodes of nocturnal 
hypoglycemia, with up to 14.7 hours of work time lost.15 
Recently reported data at the ADA 2011 Scientific Sessions 
suggested that hypoglycemia events identified from health 
care claims are associated with increased use of short-term 
disability and absenteeism leave. On average, patients with 
hypoglycemia were more likely to use these types of leave 
and had more days of leave than control patients over the 
course of a 6-month study.32
Detecting and uncovering 
hypoglycemia
The key to preventing and minimizing the inherent risks and 
costs associated with hypoglycemia is to improve monitor-
ing and detection, in particular by improving recognition of 
recurrent episodes of asymptomatic, nonsevere, or nocturnal 
hypoglycemia in patients at risk and identifying patients with 
hypoglycemia unawareness. Ultimately, the most important 
goal is for all primary care physicians to recognize that 
every patient treated with antihyperglycemic medications 
is at risk of iatrogenic hypoglycemia, and to ask patients 
about hypoglycemia at each and every visit. Table 5 lists 
questions the primary care physician can ask at each visit in 
order to highlight all hypoglycemic episodes that may have 
occurred since the last visit.33 Information gathered about 
hypoglycemic events will help primary care physicians to 
assess patient understanding of hypoglycemia and to under-
stand more about potential causes, severity, and frequency of 
hypoglycemia. This will allow them to respond appropriately 
to hypoglycemic events by counseling patients, referring 
them to educational programs, or adjusting components of the 
treatment regimen, such as short-term or long-term   glycemic 
goals, type of antidiabetes medication, and frequency or type 
of blood glucose monitoring. In patients with a history of 
hypoglycemia unawareness, a 2–3-week period of meticu-
lous avoidance of hypoglycemia should be considered as 
a first-line response.7 It is important to note that, although 
experts have proposed relaxing glycemic goals in vulnerable 
individuals such as elderly patients, studies have indicated 
that relaxing glycemic goals does not necessarily reduce 
hypoglycemic risk. For example, the American Geriatrics 
Table 3 Annual total costs per patient attributable to hypoglycemia
Study Cost year Treatment arm Mean (SD) Median Expected cost
Cobden75 2006 Insulin vial and syringe 
Biphasic insulin analog pen
$1528 ($2336) 
$620 ($899)
$490 
$142
Lee et al68 2006 Insulin vial and syringe 
Insulin analog pen
$1415 ($2556) 
$627 ($993)
$533 
$172
Misurski*,76 Data gathered 2006–2008 Exenatide 
Insulin glargine
$78 
$196
Notes: *Estimate derived from model using incidence rates (adjusted for patient characteristics) and estimated per event hypoglycemia costs based on mean and median 
costs per event pooled for both treatment groups. For ease of comparison in this table, reported cost per 100 patients has been converted to cost per patient.
Copyright © 2010, Turner white Communications, Inc. Reprinted with permission from Zhang Y, wieffer H, Modha R, Balar B, Pollack M, Krishnarajah G. The burden of 
hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives. J Clin Outcomes Manage. 2010;17(12):547–557.
Abbreviation: SD, standard deviation.
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Society 2003 guidelines34 recommend relaxing the glycemic 
goal to an HbA1c level of 8% in older patients, yet a recent 
study by Munshi et al that evaluated patients $69 years of 
age with HbA1c values $8% found an unexpectedly high 
rate of hypoglycemic episodes among this population, 
suggesting that simply relaxing HbA1c goals may not be 
adequate to protect older adults against hypoglycemia.35 
The ADA standards for 201210 recommend using the goals 
set for younger adults in older adults as well, although they 
also suggest that these goals may be relaxed for patients 
who are not functional or cognitively intact, or do not have 
a significant life expectancy.36,37
The many definitions of hypoglycemia make it particu-
larly difficult for primary care physicians to know what con-
stitutes a true episode of hypoglycemia. Widespread use of 
the ADA guidelines as recommended by the FDA could help 
to standardize recognition and treatment of hypoglycemia. It 
is also important for physicians to recognize the difficulties of 
detecting nocturnal and asymptomatic hypoglycemia, both of 
which contribute to a substantial proportion of hypoglycemic 
events and can lead to a greater incidence of severe hypo-
glycemic events because of hypoglycemia unawareness and 
hypoglycemia-associated autonomic failure and ultimately 
to serious complications, such as sudden death during sleep. 
A study using continuous glucose monitoring identified 
unrecognized hypoglycemia in 60% of patients; 73.7% of 
those episodes occurred during the night, with the highest 
incidence in children aged under 5 years.7
It is also important for primary care physicians to be 
aware of when hypoglycemic events are most likely to occur 
while patients are in their care. In addition to continuously 
monitoring patients with type 1 diabetes, physicians are likely 
to be responsible for the initiation and titration of insulin 
therapy in patients who are no longer meeting glycemic 
  targets. Hypoglycemic events are most likely to occur in these 
patients during the first 14–16 weeks following initiation of 
insulin therapy and/or during insulin dose titration.38
Table 4 Costs per hyperglycemic episode
Event severity Estimated medical 
cost/event
Estimated work  
days lost
Estimated 
indirect 
cost/event
Mild: patient experiences hypoglycemic symptoms requiring assistance  
from a second person but no medical attention is needed
€26.0 0.22 37.0
Moderate: patient seeks medical attention for hypoglycemia but is not  
admitted to hospital overnight
€334.7 0.27 45.3
Severe: patient is admitted to hospital because of hypoglycemia €2906.8 6.60 1110.6
Copyright © 2010, Turner white Communications, Inc. Reprinted with permission from Zhang Y, wieffer H, Modha R, Balar B, Pollack M, Krishnarajah G. The burden of 
hypoglycemia in type 2 diabetes: a systematic review of patient and economic perspectives. J Clin Outcomes Manage. 2010;17(12):547–557.
Table 5 Questions about hypoglycemic events to consider at 
every patient visit
•  when did the event(s) occur? (daytime versus overnight)
•    Under what circumstances did they occur? (missed meal, following 
exercise, excess medication)
•  what were the symptoms?
•  what was the blood glucose reading?
•  How did patient treat the hypoglycemia?
•    Did the patient require assistance from another person in order to 
reverse the hypoglycemia?
•  Did the hypoglycemic event reoccur later within a 24-hour period?
•    what was done? (eg, carbohydrates ingested, follow-up blood 
glucose monitoring)
•    How soon did hypoglycemia resolve? (blood glucose levels rose to 
3.9 mmol/L [70 mg/dL])
•  How fearful is the patient or the family of hypoglycemia?
•  Do they test before driving?
•    Do patients “stack insulin” (re-bolus rapid insulin analog within  
3 hours of a similar injection)?
•    At what glycemic level does the patient perceive hypoglycemia?  
(If ,0.8 mmol/L [,50 mg/dL], patient may have hypoglycemia-
associated autonomic failure)
•    Some patients prefer being “low” rather than “high” because they 
fear the consequences of acute or chronic hyperglycemia. Does your 
patient understand the consequences of hypoglycemia?
Copyright  ©  2011,  Dove  Medical  Press,  Ltd.  Reprinted  with  permission  from 
Unger J. Insulin initiation and intensification in patients with type 2 diabetes mellitus 
for the primary care physician. Diabetes Metab Syndr Obes. 2011;4:253–261.
Abbreviation: HAAF, hypoglycemia-associated autonomic failure.
Blood glucose monitoring
One way that detection of hypoglycemia can be improved is 
by careful blood glucose monitoring. This is a core compo-
nent of effective diabetes self-management in insulin-treated 
patients. There are two main options for blood glucose 
monitoring, ie, continuous glucose monitoring and self-
monitoring of blood glucose. The testing regimen depends 
upon the specific therapeutic regimen that is in use, but gen-
erally, frequent self-monitoring of blood glucose will allow 
sufficient assessment of glycemic patterns over a 24-hour 
period. Monitoring should not be limited to daytime hours 
and should include periodic nocturnal surveillance to detect 
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episodes of   nocturnal or early-morning hypoglycemia. In 
order to uncover asymptomatic hypoglycemia, hypogly-
cemia unawareness, or high-risk patterns, periodic 7-point 
profile testing should be used as outlined in the AACE 
guidelines.7
Primary care physicians play a vital role in ensuring 
appropriate blood glucose monitoring and in effectively 
evaluating the data, and must be provided with accurate, 
structured data. Structured blood glucose testing allows 
patients and physicians to identify specific glycemic pat-
terns that may be corrected with pharmacological or lifestyle 
interventions. The patterns easiest to identify and most often 
amenable to therapeutic intensification include hypoglyce-
mia, fasting hyperglycemia, and postprandial   hyperglycemia. 
Testing should be performed before and 2 hours after 
each meal for 3 days prior to the patient’s next scheduled 
  appointment. The difference between the baseline premeal 
and the 2-hour postprandial blood glucose levels is known 
as the “delta.” The meal with the highest delta becomes the 
starting point for prandial insulin.33 Recent intervention 
studies showed that there was significant improvement in 
glycemic control when physicians were provided with struc-
tured self-monitoring of blood glucose data collected and 
recorded by patients. In addition, a recent pilot study showed 
that primary care physicians presented with structured, easy-
to-visualize self-monitoring of blood glucose data recom-
mended more timely and aggressive treatment changes. In 
vulnerable patients and those with a history of hypoglycemia 
unawareness, diagnostic or real-time continuous glucose 
monitoring should be employed.39 A recent publication in 
Diabetes Care found that an automated decision support 
tool, which analyzes self-monitoring of blood glucose data, 
identifies primary glycemic abnormalities, and recommends 
appropriate therapeutic options, was as effective as clinical 
information in improving clinicians’ ability to interpret 
structured self-monitoring of blood glucose data accurately. 
A combination of education and decision support tool was 
most effective.40
In deciding upon whether to have a patient rely on 
self-monitoring of blood glucose or employ continuous 
glucose monitoring, it is important to differentiate what 
each method provides. Self-monitoring of blood glucose 
can help predict hypoglycemia, enabling the patient to make 
insulin dose adjustments that minimize the risk of develop-
ing   hypoglycemia. On the other hand, continuous glucose 
monitoring provides the patient with real-time notification 
of an impending event by means of a preset alarm or by 
visually checking the device’s display.7 Continuous   glucose 
monitoring devices have three main components, ie, a dis-
posable sensor, a transmitter, and a receiver. The sensor 
detects the presence of blood glucose; the transmitter, which 
is connected to the sensor, powers the electrochemical blood 
glucose reaction in the device; and the receiver records and 
displays the blood glucose value. The patient uses an applica-
tor or insertion device to place a subcutaneous sensor wire. 
The continuous glucose monitoring device is worn for 3, 5, 
or 7 days, depending on the continuous glucose monitoring 
system used. During the wear time, the sensor’s accuracy is 
periodically calibrated via pairing of the sensor’s values with 
capillary blood glucose values obtained from a fingerstick.
Continuous glucose monitoring not only displays real-
time interstitial blood glucose values, but sounds auditory 
alerts for extreme changes in blood glucose values. Patients 
with type 1 diabetes have evidence of dysfunctional blood 
glucose counter-regulation during sleep and are therefore at 
greater risk of developing nocturnal hypoglycemia and hypo-
glycemia-associated autonomic failure.41 Indices of central 
sympathetic activation, such as epinephrine and norepineph-
rine concentrations, are reduced during sleep in patients with 
diabetes, as are other indices, ie, heart rate, blood pressure, 
and peripheral vascular resistance, which drop during deeper 
nonrapid eye movement sleep. Impaired defenses against 
hypoglycemia during sleep may contribute to the vicious 
circle of impaired blood glucose counter-regulation when 
patients are either awake or asleep. Thus, both asymptomatic 
and symptomatic episodes of nocturnal hypoglycemia have 
potentially serious consequences for patients with diabetes. 
Any patient with a history of hypoglycemia-associated auto-
nomic failure or nocturnal hypoglycemia should be placed 
on continuous glucose monitoring.6
Structured blood glucose testing also provides a use-
ful means by which patients may learn to self-titrate their 
mealtime insulin doses. The fundamentals of insulin phar-
macokinetics and pharmacodynamics may also be concep-
tualized by patients who are either new to insulin therapy or 
those who need a refresher course after years of insulin use. 
Table 6 provides some “clinically useful” tips on interpreting 
delta values as well as some educational strategies that may 
improve glycemic control.
Patient education programs
Another tool at the disposal of primary care physicians 
is a patient education program. These programs can help 
to inform patients better about the risks of hypoglycemia 
as well as preventive measures and treatment options. In 
patients who perform self-monitoring of blood glucose less 
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Table 6 Interpretation of structured glucose testing readings
Delta value (mg/dL) Delta value (mmol/L) Interpretation Intervention
0–50 0–2.7 •    Correct insulin given for amount of 
carbohydrates consumed
•  Correct lag time procedure followed
•  None
51–100 2.8–5.5 •  Insulin-to-carbohydrate mismatch
•  Incorrect lag time
•    Possible snacking in between end  
of meal and 2-hour test
•    Increase prandial insulin dose 
1–2 units next time this type 
of food is eaten
•    Make sure to inject insulin at 
least 15 minutes prior to meals
100–200 5.5–11.1 •    Possibly had elevated blood glucose 
prior to mealtime and did not give  
a correction dose
•  Insulin-to-carbohydrate mismatch
•  was insulin omitted?
•    Errors in blood glucose monitoring  
technique
•   Teach patient how to use a 
premeal insulin sensitivity factor
•    If patient omitted insulin they 
will see the error of their ways
•    If postmeal delta is consistently 
elevated, increase baseline 
insulin dose by 1 unit per day 
until delta is 0–2.7 mmol/L 
(0–50 mg/dL) or 2-hour 
postprandial blood glucose 
value is 7.7 mmol/L  
(,140 mg/dL)
•    Educate patient on proper BG 
monitoring. Touching fruit, cakes, 
or ice cream after a meal may 
result in false elevation of BG 
values
Any negative delta value  
(eg, -25)
Any negative delta value •    Miscalculation of insulin-to-carbohydrate 
ratio: too much insulin administered for 
amount of carbohydrate eaten. Patient 
is likely to become hypoglycemic in the 
next 1–2 hours
•    Educate patient regarding insulin 
absorption principles: 1 hour 
after bolus administration, 90% 
of rapid-acting insulin analog 
remains in depot. Based upon 
the pharmacokinetics of rapid-
acting insulins (lispro, aspart, 
and glulisine), the percentage of 
insulin remaining to be absorbed 
from the depot postbolus are as 
follows: 90% at 1 hour, 60% at  
2 hours, and 40% at 3 hours. 
Thus, if 10 units of insulin are 
given at 8 am, at 10 am 6 units 
(60% of the initial bolus) remains 
to be absorbed. A premeal blood 
glucose value of 6.6 mmol/L 
(120 mg/dL) and a 2-hour 
postmeal blood glucose value of 
4.9 mmol/L (90 mg/dL) gives a 
delta of –1.6 mmol/L (–30 mg/dL). 
Because 6 units of rapid-acting 
insulin remains to be absorbed, 
a significant decline in blood 
glucose has been noted at 
2 hours after eating, and the 
patient is trending towards 
hypoglycemia. Self-monitoring 
should be repeated at 3 and 
4 hours postinjection to identify 
and correct any hypoglycemia 
(,3.3 mmol/L [,60 mg/dL]) 
events proactively
Abbreviation: BG, blood glucose.
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than optimally, which is a common issue, these programs 
can also help to educate patients about the importance of 
frequent self-monitoring of blood glucose, good record-
keeping, and communication with the primary care physician 
to improve the accuracy of the blood glucose information 
that they provide.
Patient education programs can also help to reduce 
patient fear of hypoglycemia and improve diabetes 
  management. As mentioned previously, HFS data indicate 
that previous episodes of severe hypoglycemia, or negative 
preconceptions about insulin-based treatment regimens, can 
significantly influence patient worries and behaviors about 
hypoglycemia, and fear of hypoglycemia has a significant 
clinical impact on diabetes management, metabolic control, 
and long-term health outcomes.26 There is evidence that 
blood glucose awareness training and cognitive behavioral 
therapy can help to improve diabetic management, and that 
interventions targeting health beliefs and attitudes about 
hypoglycemia and diabetes self-management can be more 
effective than knowledge-centered patient education, which 
focus on “symptom perception”, in reducing hypoglycemia 
unawareness.42
Titration algorithms
Because hypoglycemic events are more common during 
the titration period of insulin-based therapies, carefully 
  implemented insulin titration algorithms can also be employed 
when adding basal insulin to the patient’s treatment   regimen. 
This has been shown to enable better glycemic control, 
with little risk of severe hypoglycemia.43 The patient should 
be actively involved in the titration process and should be 
  provided with self-dosing titration algorithms for both basal 
and prandial insulin.
Advances in insulin therapy
In spite of the hypoglycemic risks associated with intensive 
treatment regimens, current diabetes guidelines continue to 
emphasize their importance, and the pursuit of tighter gly-
cemic control has led to earlier and more intensive use of 
insulin.7,10 Over time, most patients with type 2 diabetes will 
need to initiate insulin therapy to maintain adequate blood 
glucose levels. In fact, patients with type 2 diabetes may often 
benefit substantially from earlier introduction of insulin, but 
it is delayed due to substantial fear of hypoglycemia. These 
facts have led to the development of ever-improving insulin 
analogs and insulin-based therapies, which provide adequate 
glycemic control while limiting the attendant risk of frequent 
and/or severe hypoglycemia.
Insulin was first used in the treatment of diabetes in the 
1920s. By the 1940s, the need for a prolonged duration of 
action had driven the development of neutral protamine 
Hagedorn (NPH) insulin, which has a neutral protamine 
added to the insulin, thereby giving it an extended duration 
of action. NPH is an intermediate-acting insulin which is 
prone to a dome-shaped basal plasma profile, which leaves 
the patient vulnerable to hypoglycemic events at the peak 
of insulin action. The 1980s saw the introduction of human 
insulin, which displays suboptimal pharmacodynamic and 
pharmacokinetic properties. More recently, advances in 
molecular biology have allowed the development of insulin 
analogs, the pharmacokinetic and pharmacodynamic profiles 
of which more closely match that of endogenous insulin in a 
healthy individual (Figure 3).44 An array of clinical trials and 
observational studies has examined the efficacy and safety 
of the insulin analogs. They have consistently been shown 
to provide as good or better glycemic control than human or 
NPH insulin and to reduce the risk of hypoglycemia in both 
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Figure 3 Action profile of rapid-acting and long-acting insulin analogs and insulin analog premixes.
Copyright © 2009, UBM Medica LLC. Reprinted with permission from Brunton S. Safety and effectiveness of modern insulin therapy: the value of insulin analogs. Consultant. 
2009;Suppl:S13–S19.
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type 1 and type 2 diabetes patients in controlled trials and 
in clinical practice. However, clinical trials of insulins have 
typically employed a “treat-to-target” principle, whereby 
instead of examining fixed drug doses, investigators titrate 
the drugs under investigation to achieve a fixed treatment 
target; in the case of diabetes trials, this is typically a specific 
HbA1c target. This better enables the investigators to assess 
adverse events, such as hypoglycemia.
The ideal insulin
A number of recently created insulin analogs and those still 
under development and in clinical trials are designed specifi-
cally to address several unmet needs, with the intention to 
create the ideal insulin that will provide optimal glycemic 
control, with limited adverse effects, and improved conve-
nience to the patient. Typically, insulin therapy comprises 
a long-acting basal insulin, which mimics the background 
insulin normally produced over a 24-hour period by the 
pancreas, supplemented with a bolus or short-acting insulin, 
which mimics the normal physiological insulin response to 
ingestion of a meal.
Several key characteristics of the ideal insulin have 
been identified, which are guiding the development of new 
insulin analogs and treatment regimens. Among the most 
important of these aspects is minimal intrapatient variability 
(the same dose given on different occasions should give the 
same effect); reduced risk of hypoglycemia (the insulin[s] 
should display a flat pharmacodynamic profile associated 
with a low risk of hypoglycemia or peak relatively quickly 
to cover meals, in the case of fast-acting analogs); ease of 
administration (with the focus on reducing the number of 
daily injections and improving accuracy of dosing to improve 
adherence and avoid hypoglycemic events); flexible admin-
istration times (the insulin[s] should be adaptable to the 
patient’s needs, particularly for patients with irregular diet 
or work schedules); and superior fasting and postprandial 
blood glucose control (the control of fasting blood glucose 
is equally important to postprandial blood glucose control 
to reduce the risk of microvascular and macrovascular 
complications).45,46
Long-acting basal insulin analogs
Various efforts have been made to develop insulin analogs 
that closely mimic the pharmacokinetic profile of endogenous 
insulin. Among them are long-acting insulins, which serve 
to mimic the basal action of insulin over a 24-hour period.46 
Insulin glargine and insulin detemir are both long-acting 
insulins, with flatter insulin profiles that more closely match 
normal basal insulin release. Both gained FDA approval for 
use in patients with diabetes in the early part of the last decade 
(insulin glargine in 2000 and insulin detemir in 2005). Their 
duration of action is between 18 and 26 hours, compared with 
approximately 14.5 hours for NPH insulin.7,46 They can be 
administered 1–2 times daily for basal insulin supply. Both 
are longer-acting than NPH insulin, but insulin detemir has 
the added advantage of less intrapatient variability than both 
insulin glargine and NPH insulin, which have a similar level 
of variability (GIR-AUC(0–12 h) 27% [detemir] versus 59% 
[NPH] versus 46% [glargine], as assessed by the coefficient 
of variation for the pharmacodynamic end points studied).47 
A major advantage of these long-acting insulins is that they 
achieve similar if not better levels of glycemic control when 
studied in a treat-to-target study design, while presenting 
a substantially lower risk of overall hypoglycemic events, 
in both type 1 and type 2 diabetes patients. Patients treated 
with insulin glargine experience a 46% reduction in severe 
and 59% reduction in nocturnal hypoglycemia, compared 
with those treated with NPH insulin,46 while treatment with 
insulin detemir is associated with fewer mild hypoglycemic 
events than NPH insulin (mean rate 26.3 versus 35.5 events 
per subject over one year). Furthermore, a model developed 
to evaluate cost-effectiveness based on mild hypoglycemia 
and pharmacy costs over one year found that, although 
insulin detemir was associated with higher pharmacy costs, 
it was likely to be more cost-effective than NPH insulin in 
subjects with type 1 diabetes as the result of a reduction in 
mild   hypoglycemia.48 Patients treated with insulin detemir also 
experience a 87%–90% decrease in nocturnal   hypoglycemia.46 
In insulin-naïve patients with type 2 diabetes, basal insulin 
analogs lower the risk of all hypoglycemic events when com-
pared with NPH insulin (16% versus 26%, respectively).38 
They also demonstrate fewer hypoglycemic events than 
rapid-acting analogs and premixed formulations, which will 
be discussed in the following sections, and therefore offer 
maximum tolerability among the insulin regimens.
The biggest disadvantage with the currently available 
basal insulins is that they have to be injected at a consistent 
time every day in order to ensure optimal biological action, 
and in some patients need to be dosed twice daily to provide 
24 hours of blood glucose control. Patients may have dif-
ficulty adhering to these strict dosing schedules. For this 
reason, a new ultra long-acting insulin has recently been 
submitted to the FDA for review, ie, insulin degludec. Insulin 
degludec is an ultra long-acting novel insulin preparation, 
the action profile of which is primarily attributable to the 
formation of soluble multihexamers at the injection site. 
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Inside the insulin pen, the insulin dihexamers are bound by 
phenol. Following an injection into the subcutaneous depot, 
the phenol is dispersed, allowing the hexamers to disassoci-
ate and be absorbed from the interstitial space. The insulin 
degludec monomers are bound to the multiheximers by zinc. 
The zinc gradually separates from the multihexamers result-
ing in a slow, continuous and predictable delivery of insulin 
degludec monomers from the subcutaneous injection depot 
into the circulation.49 The monomers are reversibly bound to 
albumin and carried to their receptor sites in the periphery. 
Once steady state is reached, the mean half-life is 25.1 hours50 
and the duration of action is up to 42 hours.51 Insulin deglu-
dec reduced the risk of confirmed nocturnal hypoglycemia 
when compared with insulin glargine in patients with type 1 
diabetes52 and reduced the risk of confirmed nocturnal and 
confirmed overall hypoglycemia when compared with insulin 
glargine in patients with type 2 diabetes.53
The safety and efficacy of the prolonged half-life of 
insulin degludec has been tested by using extreme dosing 
intervals of 8–40 hours in patients with type 2 diabetes and 
comparing their HbA1c levels and safety data with those 
from patients receiving insulin glargine injected at the same 
time each day for 26 weeks.54 Both the insulin degludec 
and glargine patients demonstrated similar reductions from 
baseline HbA1c (-1.28% and -1.26% points, respectively). 
The mean fasting blood glucose at week 26 was significantly 
lower for insulin degludec than for glargine (5.8 versus 
6.2 mmol/L [104 versus 112 mg/dL]; P = 0.04). The mean 
daily doses of the two insulins were similar between groups, 
as were rates of confirmed and nocturnal hypoglycemia.54 
Thus, flexible dosing at any time of day does not compro-
mise glycemic control or increase the risk of hypoglycemia 
in patients with type 2 diabetes when compared with insulin 
glargine. From a clinical perspective, the flexibility of insulin 
degludec may be useful for patients who travel, are shift 
workers, or prefer to sleep later on weekends without having 
to worry about developing hyperglycemia if the timing of 
their routine insulin injections is disrupted.
Rapid-acting bolus insulin analogs
A number of rapid-acting insulin analogs have also been 
developed to mimic more closely the mealtime insulin 
response. These include insulin lispro, insulin aspart, and 
insulin glulisine, which are quickly absorbed into the system, 
and have a rapid onset, and a short duration of action. In this 
way, they reduce postprandial blood glucose excursions and 
help to lessen the risk of hypoglycemia in the periods between 
meals. Overall, patients taking rapid-acting insulin analogs 
experience far fewer episodes of all types of hypoglycemia 
compared with those on human insulin. A Cochrane review of 
clinical studies clearly illustrated this reduction in hypoglyce-
mic risk, finding a median 21.8 episodes per 100 person-years 
in type 1 diabetes and 0.3 in type 2 diabetes, for rapid-acting 
insulin analogs, compared with 46.1 episodes per 100 person-
years in type 1 diabetes and 4.1 in type 2 diabetes for human 
insulin.55 Rapid-acting analogs are also particularly effective 
at reducing the risk of nocturnal hypoglycemia. For example, 
one study found that 1.3% of patients experienced major 
nocturnal hypoglycemic events with insulin aspart versus 
3.4% of patients with human insulin.56 Another study found 
that only 52 patients experienced nocturnal hypoglycemia 
with insulin lispro, compared with 181 patients with human 
insulin.57 Data assessing the effect of insulin glulisine on 
the risk of hypoglycemia are less abundant; however, it 
has been shown to have effects comparable with those of 
insulin lispro, with 3.64 symptomatic hypoglycemic events 
per patient-month, compared with 3.48 for insulin lispro.58 
Rapid-acting insulins have the lowest intrapatient vari-
ability compared with human insulin and intermediate and 
long-acting insulins.59 These insulin analogs also offer much 
greater patient flexibility in dosing times, allowing dosing at 
or even during mealtimes, compared with 30 minutes prior 
to a meal with human insulin.
Biphasic insulin analog premixes
Normally, patients with diabetes need to take multiple bolus 
injections and a basal injection each day. The number of 
injections facing patients with diabetes on this regimen is a 
significant barrier to adherence. The need for a convenient, 
effective, and simultaneous supplementation of basal and 
bolus insulin with fewer injections led to the development of 
premixed formulations of biphasic human insulin, contain-
ing a combination of a short-acting and intermediate acting 
insulin in standard proportions.
With the development of insulin analogs, newer premixes 
have become available that incorporate these analogs. While 
human premixed formulations contain 70% NPH and 30% 
regular human insulin as the basal and prandial components, 
respectively, biphasic insulin analogs, in contrast, consist of a 
mixture of a rapid-acting insulin analog and its intermediate-
acting protaminated form as the basal component. These 
include biphasic insulin aspart (70/30), biphasic insulin lispro 
(75/25), and biphasic insulin lispro (50/50).
In general, biphasic insulins should be used with caution in 
patients with less structured lifestyles and eating habits,7 but 
they do offer a number of advantages. First, they   demonstrate 
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improved glycemic control compared with human insulin 
premixes and basal insulins. They also improve patient 
adherence with therapeutic regimens, because they reduce the 
number of injections and require less monitoring compared 
with basal-bolus therapy. The rapid-acting component more 
closely mimics the physiological mealtime profile of insulin, 
and is more rapidly absorbed and cleared from the system, 
thus biphasic insulin analogs can be administered closer to 
mealtimes. Finally, though the human insulin premixes and 
insulin analog premixes exhibit the same number of minor 
hypoglycemic events (approximately 60%), the insulin 
analog premixes have been reported to reduce the risk of 
major hypoglycemic events compared with premixed human 
  insulin.44 For example, a 12-week study of patients with 
type 1 or type 2 diabetes showed that patients treated with 
biphasic insulin aspart experienced half as many major hypo-
glycemic episodes compared with those treated with biphasic 
human insulin (20 versus 42 episodes), although the overall 
risk of either major or minor hypoglycemia did not differ sig-
nificantly between treatments.60 When the study was extended 
to 2 years in patients with type 2 diabetes, the proportion of 
patients experiencing major hypoglycemia was significantly 
lower at year 2 (biphasic insulin aspart 0%, biphasic human 
insulin, 10%; P = 0.04).61 When measured using a continuous 
glucose monitoring system, nocturnal hypoglycemia has also 
been reported to occur less frequently with insulin analog 
premixes than with premixed human insulin (6.4% of time 
versus 7.9%, respectively; P = 0.018).62
The physiochemical properties of the current basal ana-
logs (glargine and detemir) do not allow for a true combi-
nation of a rapid-acting insulin with a basal insulin analog, 
because this combination is incompatible. Thus, the premixes 
and biphasic insulins brought to the market to date have 
always used the combination of a single insulin, with the 
addition of protamine creating the biphasic/mix properties. 
The ultra long-acting insulin degludec, which is currently 
under development, for the first time allows the generation 
of a true combination of a basal insulin and a rapid-acting 
analog. Insulin degludec/insulin aspart is a soluble coformu-
lation of insulin degludec (70%) and insulin aspart (30%). In 
a study comparing the coformulation with insulin glargine, 
70/30 degludec/aspart provided overall glycemic control 
comparable with that of insulin glargine, with similar low 
rates of hypoglycemia.63
Advances in insulin delivery
Typically in the US, insulin is injected with a syringe and 
vial, and there are two main modes of administration, ie, 
multiple daily injection, where patients inject a fixed amount 
of insulin, and continuous subcutaneous insulin injection, 
which allows for incremental insulin administration and 
more physiological insulin delivery. The general belief is that 
intensive insulin administration is associated with increased 
hypoglycemic risk, but studies have shown that in fact there 
is a significant decrease in the risk of hypoglycemia with 
continuous subcutaneous insulin injection when compared 
with multiple daily injection.7 However, continuous subcu-
taneous insulin injection poses a substantial financial and 
personal commitment.
The ultimate challenge in treating insulin-requiring dia-
betes is to design a reliable “closed-loop” sensor-augmented 
insulin pump. These insulin delivery devices incorporate 
data transmitted from real-time continuous interstitial blood 
glucose sensors directly to the insulin pump. The patient will 
receive an infusion of insulin commensurate with ambient 
interstitial blood glucose readings.
The safety and efficacy of the sensor-augmented pump 
was evaluated in the 1-year randomized phase of the Sensor-
Augmented Pump Therapy for A1C Reduction (STAR) 
3 study in patients with type 1 diabetes.64 Compared with 
subjects using multiple daily injections, those using sensor-
augmented pump experienced greater reductions in HbA1c 
levels by 3 months, which persisted for the duration of the 
study. A group of patients on multiple daily injections within 
STAR 3 were allowed to switch to sensor-augmented pump 
therapy for 6 months at the conclusion of the one-year trial.65 
Patients on the sensor-augmented pump were also allowed to 
remain on their therapy for an additional 6 months, extend-
ing the STAR 3 study to 18 months. Of the 443 patients 
who completed the one-year study, 420 elected to continue 
for an additional 6 months. Two hundred and four (94%) of 
the patients on the sensor-augmented pump continued their 
initial augmented pump therapy, while 190 (93%) of the 
subjects on multiple daily injections decided to cross over 
to the sensor-augmented pump group.
During the study phase of STAR 3, the HbA1c levels were 
reduced by approximately 0.5%–0.6% more with sensor-
augmented pump treatment compared with multiple daily 
injections. Patients switching from multiple daily injections 
to the sensor-augmented pump during the continuation phase 
reduced their HbA1c levels by a similar percentage. Patients 
who wore the sensor at least 60% of the time demonstrated 
maximal lowering of HbA1c levels.
The sensor-augmented pump technology has also dem-
onstrated efficacy in automatically suspending basal insulin 
delivery for up to 2 hours in response to sensor-detected 
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hypoglycemia in patients with type 1 diabetes.66 The abil-
ity of the sensor to suspend insulin delivery automatically 
without patient intervention is an important step in closing 
the loop.
Another development in the administration of insulin is 
the introduction of pen injector systems. There are two types 
of pen devices, which have either replaceable or prefilled 
cartridges, the latter of which can be completely disposed 
of (including the pen) when empty. Pen injectors have been 
shown to improve ease of administration, patient satisfaction. 
and adherence (by up to 75%–80%), and allow more precise 
dosing in a single injection.67 The 32-gauge needles used in 
the delivery of insulin in these injector pens are virtually 
painless.33 Switching from a syringe and vial to an injector 
pen has also been shown to reduce the risk of hypoglycemic 
events by 50%,68 as well as to reduce the cost associated 
with hypoglycemia (see Table 3).29 Insulin titration may be 
better performed using a pen injector because this device can 
provide accurate titrations of one-unit increments of insulin 
per meal with a simple twist of the dial.33 In spite of the 
advantages, the use of pen devices in the US remains low in 
comparison with other developed countries, with only 15% 
of patients thought to use them.67
Given that errors in insulin administration remain high, 
pens may provide a clear opportunity for increasing insu-
lin safety and reducing the risk of accidental iatrogenic 
  hypoglycemia. A retrospective search, for example, was 
performed for all records related to unintentional insulin 
overdoses at nine poison centers in four US states   (Kentucky, 
Louisiana, Texas, and Kansas, comprising a pool of 
36   million people) for the years 2000–2009.69 Unintentional 
therapeutic errors were defined as any insulin provided in a 
manner that is an unintentional deviation from a proper thera-
peutic regimen and results in an incorrect route of adminis-
tration, wrong dose, administration to the wrong person, or 
administration of the wrong substance. As reported to the 
nine poison centers, there were 2584 unintentional thera-
peutic errors involving insulin. During this 10-year reporting 
period, there was a 495% increase in the annual incidence 
of unintentional therapeutic errors involving insulin, with a 
mean annual increase of 28%.
As the diabetes population ages, physicians must con-
sider prescribing insulin that can be administered in the 
safest and most effective manner. In addition, patients are 
more frequently being provided the opportunity to self-
titrate their basal and prandial insulin doses ambitiously in 
order to achieve their targeted glycemic levels in a timely 
  manner. Pen devices allow patients to self-titrate their doses 
of   insulin safely and accurately. Pen devices are color-coded 
and texture-coded, which minimizes the risk of confusion 
as to which injections are provided as basal, mixed, or pran-
dial insulin. New-generation pens will provide a reduction 
in injection force and dosing accuracy over a broad range 
of insulin doses.70
Alternative treatment strategies
Other developments in options for the treatment of diabetes 
address the need for reducing hypoglycemic risk while 
maintaining optimal glycemic control. These include the 
incretins, gastrointestinal hormones that stimulate postpran-
dial release of insulin from β-cells. The incretin system can 
be pharmacologically influenced in two different ways, ie, via 
glucagon-like peptide-1 receptor agents, including exenatide 
and liraglutide, and dipeptidyl peptidase-4 inhibitors 
(dipeptidyl peptidase-4 regulates glucagon-like peptide-1 
activity), which include sitagliptin, vildagliptin, and saxa-
gliptin, among others. The so-called “incretin effect” is 
responsible for 50%–70% of postprandial insulin release in 
healthy individuals.
The incretins have the advantage of an extremely low 
hypoglycemic risk when used as monotherapy. However, 
it is important to remember that this feature may be lost, 
and hypoglycemia may occur when these agents are used 
in combination with insulin or insulin secretagogues such 
as   sulfonylureas. For example, exenatide has a 5% hypogly-
cemic risk as a monotherapy, which increases to 35% when 
combined with a sulfonylurea.71 Combination therapy of 
incretins with basal insulin can also be effective for insulin-
naïve patients with type 2 diabetes whose disease is subop-
timally controlled with oral agents.72,73 In October, 2011, the 
FDA approved the use of exenatide as an addon therapy to 
insulin glargine, with or without metformin or thiazolidin-
edione, in conjunction with diet and exercise for adults with 
type 2 diabetes. In a study examining the expanded use of 
exenatide, 261 patients receiving insulin glargine, with or 
without metformin or a thiazolidinedione, were randomly 
assigned to receive 10 µg of exenatide (n = 138) or placebo 
(n = 123) and were stratified by baseline HbA1c level (#8% 
or .8%).72 At randomization, patients with an HbA1c 
level #8% had their insulin glargine dose reduced by 20%.
After 5 weeks, all patients underwent aggressive insulin 
titration to a target fasting blood glucose of ,5.6 mmol/L 
(,100 mg/dL). At 30 weeks, HbA1c reduction from base-
line with exenatide plus insulin glargine was greater than 
with glargine alone (-1.74% points versus -1.04% points; 
P , 0.001). In addition, 60% of patients in the exenatide 
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group versus 35% in the glargine-alone group achieved a 
target HbA1c level of #7% (P , 0.001). Further, 40% of 
patients using exenatide versus 12% of patients using glargine 
alone achieved a target HbA1c of #6.5% (P , 0.001). All 
patients had lower fasting blood glucose concentrations, 
although patients receiving exenatide had generally improved 
postprandial blood glucose control compared with patients 
in the placebo group. Patients in the exenatide arm also lost 
an average of 1.8 kg (4 lb), whereas patients in the insulin 
glargine-only arm gained 1 kg (2.2 lb; P , 0.001). No 
increased risk for hypoglycemia was noted in the exenatide 
group, and nausea was the most commonly reported adverse 
event.72
Used as monotherapy or in combination with other 
blood glucose-lowering agents, incretins would be most 
beneficial in patients with type 2 diabetes mellitus who have 
multiple comorbidities, elderly patients who live alone, or 
patients at high risk of falls, because these patients may 
be unable to respond appropriately to an episode of severe 
hypoglycemia or may be at increased risk of hypoglycemia 
unawareness.6,74
Conclusion
Iatrogenic hypoglycemia represents a much more substantial 
barrier to the effective control of blood glucose concentra-
tions in patients with diabetes than is currently appreciated. 
Greater awareness and detection of all hypoglycemic events 
by careful monitoring, adherence to guidelines, and use 
of optimal treatment combinations is needed in order to 
prevent the serious medical and economic consequences 
associated with this adverse effect of antihyperglycemic 
medications. There is a need for improved patient and pro-
vider education on optimal detection and understanding of 
hypoglycemia and the benefits of accurate blood glucose 
measurement, which together can help to reduce the risk 
and fear of hypoglycemia, hypoglycemia unawareness, and 
hypoglycemic events.
Intensive insulin regimens are required in order to meet 
tighter glycemic goals, but carry an inherently increased 
risk of hypoglycemia. Though much progress has been 
made in recent years with the introduction of rapid-acting 
insulin analogs and biphasic premixes, there is a continuing 
need for newer therapeutic agents that carry lower risks of 
hypoglycemia, while maintaining optimal glycemic control 
and improving patient adherence. Therapeutic advances are 
continually being made, and insulins that ever more closely 
match the physiological profile of human insulin are on the 
horizon.
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